{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:32:50Z","timestamp":1794997970040,"version":"4.9.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T00:00:00Z","timestamp":1256256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>To cite this article:<\/jats:bold>\n                      Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Ant\u00e9para I, J\u00e1uregui I, Valiente R, the Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20\u2003mg\n                      <jats:italic>vs<\/jats:italic>\n                      levocetirizine 5\u2003mg for the treatment of chronic idiopathic urticaria: a multi\u2010centre, double\u2010blind, randomized, placebo\u2010controlled study.\n                      <jats:italic>Allergy<\/jats:italic>\n                      2010;\n                      <jats:bold>65<\/jats:bold>\n                      : 516\u2013528.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Background:\u2002<\/jats:bold>\n                      Bilastine is a novel nonsedative H\n                      <jats:sub>1<\/jats:sub>\n                      \u2010receptor antagonist, which may be used for the symptomatic treatment of chronic idiopathic urticaria (CU). The aim of this study was to compare the clinical efficacy and safety of bilastine 20\u2003mg\n                      <jats:italic>vs<\/jats:italic>\n                      levocetirizine 5\u2003mg and placebo in CU patients with moderate\u2010to\u2010severe symptoms.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Methods:\u2002<\/jats:bold>\n                      Overall 525 male and female subjects aged 18\u201370\u2003years were randomized to receive bilastine 20\u2003mg, levocetirizine 5\u2003mg or placebo, once daily for 28\u2003days, in double\u2010blind manner, in 46 centres across Europe and Argentina. Patients rated symptoms of pruritus, number of wheals, and maximum size of wheals (on predefined scales) as reflective (over past 12\u2003h) symptoms twice daily, for assessment of change from baseline in the total symptoms scores (TSS) over 28\u2003days as the primary efficacy measure. Changes in reflective and instantaneous symptoms scores, Dermatology Life Quality Index (DLQI), and CU\u2010associated discomfort and sleep disturbance were assessed as secondary outcomes. Safety was assessed according to adverse events, laboratory tests and electrocardiograms.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Results:\u2002<\/jats:bold>\n                      Bilastine reduced patients\u2019 mean reflective and instantaneous TSS from baseline to a significantly greater degree than placebo (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001); from day 2 onwards of treatment. The DLQI, general discomfort, and sleep disruption were also improved significantly in bilastine\u2010treated patients as compared with placebo\u2010treated patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.001 for all parameters). Comparison with levocetirizine indicated both treatments to be equally efficacious as well as equally safe and well tolerated as compared with placebo.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Conclusions:\u2002<\/jats:bold>\n                      Bilastine 20\u2003mg is a novel effective and safe treatment option for the management of CU.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1398-9995.2009.02217.x","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T10:56:47Z","timestamp":1256295407000},"page":"516-528","source":"Crossref","is-referenced-by-count":125,"title":["Comparison of the efficacy and safety of bilastine 20\u2003mg\n                    <i>vs<\/i>\n                    levocetirizine 5\u2003mg for the treatment of chronic idiopathic urticaria: a multi\u2010centre, double\u2010blind, randomized, placebo\u2010controlled study"],"prefix":"10.1111","volume":"65","author":[{"given":"T.","family":"Zuberbier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bogacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ant\u00e9para","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"J\u00e1uregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Valiente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Bilastine International Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464220-00003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00276.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200310000-00008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02678.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00964.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_6_8_2","first-page":"119","article-title":"Review of H1 antihistamines in the treatment of chronic idiopathic urticaria","volume":"76","author":"Monroe E","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"e_1_2_6_10_2","volume-title":"Bilastine (F\u201096221\u2010BMI): a novel antihistamine compound for the treatment of allergic rhinitis and chronic idiopathic urticaria","author":"Faes Farma SA"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506060-00005"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200607040-00002"},{"key":"e_1_2_6_13_2","article-title":"Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10\u2003mg cetirizine","volume":"47","author":"Sologuren A","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"e_1_2_6_14_2","article-title":"In vitro hepatic metabolism of [14 C] bilastine","volume":"39","author":"Lucero ML","year":"2007","journal-title":"Drug Metabol Rev"},{"issue":"1","key":"e_1_2_6_15_2","first-page":"200","article-title":"The disposition, metabolism and elimination in rats of bilastine, a potent selective H1 receptor antagonist","volume":"39","author":"Mumford R","year":"2007","journal-title":"Drug Metabol Rev"},{"issue":"1","key":"e_1_2_6_16_2","first-page":"148","article-title":"The pharmacokinetics of bilastine after single and 14\u2003days once daily administration","volume":"101","author":"Crean C","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818b2091"},{"issue":"88","key":"e_1_2_6_18_2","first-page":"85","article-title":"Lack of significant effect of bilastine on ventricular repolarization. A thorough QT\/QTc study","volume":"63","author":"Sologuren A","year":"2008","journal-title":"Allergy"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01813.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03257.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01726.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61466-4"},{"issue":"3","key":"e_1_2_6_24_2","article-title":"A double\u2010blind, randomized, dose\u2010ranging trial in four parallel groups of 10, 20, and 30\u2003mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopathic urticaria (CU)","volume":"17","author":"Audicana MT","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_6_25_2","article-title":"Effects of age and gender on the pharmacokinetics and pharmacodynamics of bilastine","volume":"47","author":"Roupe K","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708010-00005"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.143"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61325-7"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62515-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70091-6"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02609.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07049.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.5.859"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464050-00008"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0954-7894.2002.01314.x"},{"key":"e_1_2_6_37_2","first-page":"145","article-title":"H1 antihistamines. Current status and future directions","volume":"1","author":"Simons FER","year":"2008","journal-title":"WAO J"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08920.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2009.02217.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2009.02217.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:35:12Z","timestamp":1698726912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2009.02217.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1398-9995.2009.02217.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02217.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}